University of Cincinnati (Ohio)

OAKLAND, N.J., Dec. 24, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Barry I. Gold, is acknowledged as a 2024 Pinnacle VIP Member for his contributions as a Retired Pharmacologist and Author. Barry I. Gold, a retired pharmacologist and accomplished author, has dedicated his career to addressing critical issues in the field of biochemical pharmacology and advocating for addiction awareness and effective treatments. His expertise and advocacy have made him a notable figure in the medical community. Continue Reading Barry I. Gold With a background in biochemical pharmacology, Barry I. Gold has contributed significantly to the field through his published works and research. His passion for addressing addiction issues has driven him to write a thought-provoking book titled "We're Overdosed," which provides a comprehensive exploration of the history of opioids and the urgent need for effective addiction treatment. One of Barry's primary advocacy focuses is the importance of addressing addiction through federal legislation. He emphasizes the need for comprehensive measures to prevent the illicit drug trade and ensure individuals have access to evidence-based addiction treatments. His work underscores the critical role that federal legislation plays in curbing addiction and saving lives. As a retired pharmacologist and accomplished author, Barry I. Gold's contributions extend beyond his professional expertise. He is an active member of the American Society for Pharmacology and Experimental Therapeutics (ASPET), highlighting his dedication to staying connected with the latest advancements in pharmacology and research. While Barry's professional achievements are significant, he also values the support and love of his children, expressing his gratitude for their unwavering encouragement throughout his journey. Barry's academic journey includes a Bachelor of Science (B.S.) in Zoology from the University of Cincinnati, a Ph.D. in Pharmacology from Boston University, and a postdoctoral fellowship at Yale University School of Medicine. Beyond his professional pursuits, Barry enjoys spending time with his family and pursuing his passion for writing. His favorite vacation place is North Carolina, where he finds inspiration and relaxation. Although he is retired, Barry I. Gold's commitment to addressing addiction and advocating for evidence-based treatments remains steadfast. He believes in the importance of being prepared to pivot if one makes an error in their career choice, emphasizing the need for adaptability and a commitment to making a positive impact. Barry's career accomplishments are highlighted by his books, and he is currently working on a new project, memoir entitled "Boomer Dad," reflecting his continued dedication to sharing insights and knowledge with the world. Barry I. Gold's scientific perspective and advocacy for addiction awareness serve as a source of inspiration for the medical community and individuals striving to make a difference in the field of pharmacology and addiction treatment. Contact: Katherine Green 516-825-5634 [email protected] SOURCE The Inner Circle WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

LOS ANGELES, Dec. 17, 2024 /PRNewswire/ -- Sports and recreational injuries send more than 3.5 million Americans to the hospital emergency room each year according to the National Safety Council. The problem is much greater in collegiate sports, where NCAA injury incident reports reached 1.3 million in 2022. Beyond soft tissue damage, these injuries include life-altering Anterior Cruciate Ligament (ACL) tears and Traumatic Brain Injuries. To reduce the occurrence and impact of sports-related injuries, CLR Neurosthenics today launched CLR Advantage™, a groundbreaking solution that employs interactive software and a wearable, wireless sensor network to collect real-time neurophysiological data while athletes perform pre-programmed physical exercises, cognitive tests, reaction games and position drills. This data is then used to instantly generate reports that reveal hidden deficiencies, indicate player readiness, and guide training routines for injury prevention, performance optimization and rehabilitation. Designed by a team of leading sports neurophysiologists and biometric engineers, patent-pending CLR Advantage™ utilizes FDA-approved qEEG brain wave sensors and physiological monitors to capture a continuous stream of high-resolution data, including cortical power, heart rate, heart rate variability, respiration rate, trapezoidal tension, galvanic skin response and peripheral temperature. The solution then employs NASA technology to process biometric signals and report on neurophysiological capabilities, including brain connectivity, power, activation and symmetry during various physical tasks and mental exercises. CLR Advantage™ finally correlates event-marked physiologic data to reinforce neurologic observations. For example, data may indicate certain risk in an athlete that exhibits an elevated heart rate, neurologic asymmetry and qEEG inhibition during a single-leg balance exercise. CLR Advantage™ recently completed a two-year clinical trial with 177 NCAA Division I athletes at the University of Cincinnati. Performed in partnership with Select Medical at the University's Sports Medicine Department, the study compared the neurophysiological performance of healthy athletes with those suffering from ACL injuries. Results from the study, which continues to assess injured athletes through various stages of rehabilitation, were published in the International Journal of Sports Physical Therapy. To supplement ongoing research, CLR Advantage™ is currently employed by the NFL Professional Football Athletic Trainers Society (PFATS) to study ACL injury propensity through assessments that include a variety of dynamic force exercises. "For the first time, we now have a better understanding of exactly how the brain is impacted by an acute injury," said Robert Mangine, Senior Athletic Director of Sports Medicine at the University of Cincinnati and Residency Director for NovaCare Rehabilitation. "CLR Advantage™ allows us to look at brain activity as athletes progress through the rehabilitation, then use that data and musculoskeletal measures to determine a safe return to play." The Microsoft Azure cloud-powered CLR Advantage™ platform provides an end-to-end, HIPAA-compliant solution for operators to organize teams, create athlete profiles, schedule appointments, conduct assessments, monitor live biometric data, and generate comprehensive analytic reports. Offered on a subscription basis, the solution is available for demonstration at CLR Neurosthenics' Los Angeles Assessment Center. For additional information contact: Mark O'Bryan (424) 256-7264 [email protected] 1 2; Robert L. Parisien et. al., Implementation of an Injury Prevention Program in NCAA Division I Athletics Reduces Injury-Related Health Care Costs. 9 Orthopedic J. of Sports Med. (2023). SOURCE CLR Neurosthenics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

LOS ANGELES--( BUSINESS WIRE )--A recent Children's Hospital Los Angeles study led by Principal Investigator Michael Goran, PhD , and Rachel Schenker, MD, a Fellow in the CHLA Liver Transplant Program , has found a novel combination of plasma-based biomarkers that could potentially predict liver fibrosis linked to metabolic dysfunction‐associated steatotic liver disease (MASLD)—the most common pediatric liver disease in the U.S. The study findings were published in the Journal of Pediatric Gastroenterology and Nutrition. The combined presence of these biomarkers—a metabolite called dihydroxyacetone phosphate (DHAP) and an enzyme, alanine transaminase (ALT)—could flag early signs of liver fibrosis (scarring due to long term inflammation or damage), particularly in Latino adolescents with obesity who are at elevated risk for MASLD. Liver fibrosis is currently diagnosed by invasive biopsies or imaging: “There is an urgent need for more accessible, noninvasive, and cheaper screening methods, particularly for high-risk populations such as Latino adolescents with obesity,” says Dr. Goran, Director of the Nutrition and Obesity Program in the Saban Research Institute of Children’s Hospital Los Angeles. “We want to identify this disease early while the liver damage of MASLD can still be reversed.” When Latino adolescents can be at higher risk for MASLD Between 10%–15% of Latino adolescents and 30%–40% of adolescents with obesity develop MASLD, compared to 5%–10% of the general adolescent population. This higher risk among Latino adolescents is due to high rates of obesity, which causes fat deposition and inflammation in the liver, as well as genetics—about 50% of people with Latino ethnicity have a genetic mutation that raises risk for MASLD. Prospecting in plasma Using data and patient samples from the Healthy Eating through Reduction of Excess Sugar (HEROES) trial, a 12-week study of 93 Latino adolescents with obesity funded by an RO1 grant from the National Institute of Minority Health and Health Disparities, the researchers analyzed blood serum plasma using metabolomics and DNA, and measured liver fat fraction and stiffness. DHAP, a marker of triglyceride synthesis, was significantly associated with fibrosis. Independently, ALT—a nonspecific marker of liver inflammation—was equally associated. DHAP and ALT combined were better at predicting liver fibrosis in combination than either alone. “The combination of ALT and DHAP holds significant promise as a potentially low‐cost, noninvasive screening tool for fibrosis in Latino adolescents with obesity,” says Dr. Schenker. “Future studies will need to investigate if this could be an effective screening tool for the entire population.” Collaborators included Rohit Kohli, MBBS, MS , Chief of the Division of Gastroenterology, Hepatology and Nutrition at Children’s Hospital Los Angeles. Cholsoon Jang, PhD, and Cuauhtemoc Ramirez, UCI School of Medicine analyzed the data; Hooman Allayee, PhD, Keck School of Medicine of USC; and Xueheng Zhao, PhD, and Kenneth Setchell, PhD, Cincinnati Children’s Hospital Medical Center conducted metabolomics for the study. About Children’s Hospital Los Angeles Founded in 1901, Children’s Hospital Los Angeles is at the forefront of pediatric medicine and is the largest provider of hospital care for children in California. Children’s Hospital is home to renowned experts who work together across disciplines to deliver inclusive and compassionate care, and drive advances that set pediatric standards across the nation and around the globe. Children’s Hospital Los Angeles delivers a level of care that is among the best in the world for a truly diverse population of children. The Hospital is consistently ranked in the top 10 in the nation on U.S. News & World Report’s Honor Roll of Best Children’s Hospitals. CHLA is the top-ranked children’s hospital in California and the Pacific U.S. region for 2024-25. Children’s Hospital Los Angeles embraces the hospital’s mission to create hope and build healthier futures. Children’s Hospital Los Angeles is among the top 10 children’s hospitals for National Institutes of Health funding. The Saban Research Institute of Children's Hospital Los Angeles supports the full continuum of research, allowing physicians and scientists to translate discoveries into treatments and bring answers to families faster. The pediatric academic medical center also is home to one of the largest training programs for pediatricians in the United States. And the hospital’s commitment to building strong communities is evident in CHLA’s efforts to fight food insecurity, enhance health education and literacy, and introduce more people to careers in health care. To learn more, follow CHLA on Facebook , Instagram , LinkedIn , YouTube and X , formerly known as Twitter, and visit CHLA.org/blog .